Codexis Narrows Q2 Loss on R&D Revenue Surge, Equity Infusion

TL;DR

**CDXS is still burning cash, but the massive R&D revenue jump and fresh equity raise are a bullish sign for future growth and stability.**

AI Summary

CODEXIS, INC. (CDXS) reported a net loss of $13.272 million for the three months ended June 30, 2025, an improvement from the $22.755 million net loss in the same period last year. Total revenues significantly increased to $15.328 million for Q2 2025, up from $7.979 million in Q2 2024, primarily driven by a substantial rise in research and development revenue to $7.948 million from $1.720 million. Product revenue also saw an increase to $7.380 million from $6.259 million. For the six months ended June 30, 2025, the net loss was $33.960 million, slightly better than the $34.260 million loss in the prior year period, despite total revenues decreasing to $22.871 million from $25.052 million. The company's cash and cash equivalents increased to $26.761 million as of June 30, 2025, from $19.264 million at December 31, 2024, bolstered by $17.268 million from equity sales agreements and $9.897 million from long-term debt proceeds. Operating expenses decreased to $28.190 million in Q2 2025 from $30.711 million in Q2 2024, mainly due to lower selling, general and administrative expenses.

Why It Matters

Codexis's ability to significantly increase R&D revenue and secure substantial equity financing is crucial for its long-term viability in the competitive enzyme and protein engineering market. The improved net loss, despite a six-month revenue dip, suggests a potential shift in business strategy or project milestones being met, which could signal a more stable financial footing for investors. For employees, this indicates continued investment in core technology and potential for future growth. Customers may benefit from accelerated product development, while the broader market watches to see if Codexis can translate R&D success into sustained profitability against larger biotech players.

Risk Assessment

Risk Level: medium — The company reported a net loss of $33.960 million for the six months ended June 30, 2025, and continues to operate at a loss, indicating ongoing financial challenges. While cash and cash equivalents increased, the company's total assets decreased from $149.011 million to $138.246 million, and total stockholders' equity declined from $66.927 million to $55.631 million, suggesting a weakening balance sheet despite recent financing activities.

Analyst Insight

Investors should monitor CDXS's progress in converting its increased R&D revenue into sustainable product revenue and profitability. The recent equity raise provides a capital cushion, but continued net losses and declining equity warrant caution. Consider this a speculative play on their CodeEvolver platform's future commercial success.

Financial Highlights

debt To Equity

0.71

revenue

$15.328M

operating Margin

-83.9%

total Assets

$138.246M

total Debt

$39.373M

net Income

($13.272M)

eps

($0.16)

gross Margin

72.3%

cash Position

$26.761M

revenue Growth

+92.1%

Revenue Breakdown

Key Numbers

• $15.328M — Total Revenues Q2 2025 (Increased from $7.979M in Q2 2024, a 92% increase.)
• $7.948M — R&D Revenue Q2 2025 (Significantly up from $1.720M in Q2 2024, a 362% increase.)
• $(13.272M) — Net Loss Q2 2025 (Improved from $(22.755M) in Q2 2024, a 41.7% reduction in loss.)
• $26.761M — Cash and Cash Equivalents (As of June 30, 2025, up from $19.264M at Dec 31, 2024.)
• $17.268M — Equity Sales Proceeds (New capital raised through equity sales agreements in H1 2025.)
• $9.897M — Long-term Debt Proceeds (Additional financing secured in H1 2025.)
• $(0.16) — Net Loss Per Share Q2 2025 (Improved from $(0.32) in Q2 2024.)
• $55.631M — Total Stockholders' Equity (As of June 30, 2025, down from $66.927M at Dec 31, 2024.)

Key Players & Entities

• CODEXIS, INC. (company) — registrant
• $13.272 million (dollar_amount) — net loss for Q2 2025
• $22.755 million (dollar_amount) — net loss for Q2 2024
• $15.328 million (dollar_amount) — total revenues for Q2 2025
• $7.979 million (dollar_amount) — total revenues for Q2 2024
• $7.948 million (dollar_amount) — research and development revenue for Q2 2025
• $1.720 million (dollar_amount) — research and development revenue for Q2 2024
• $33.960 million (dollar_amount) — net loss for six months ended June 30, 2025
• $17.268 million (dollar_amount) — proceeds from equity sales agreements
• $9.897 million (dollar_amount) — proceeds from long-term debt

FAQ

Risk Factors

• Cash Burn and Need for Future Financing [high — financial]: The company reported a net loss of $13.272 million in Q2 2025 and a net loss of $33.960 million for the six months ended June 30, 2025. While cash and cash equivalents increased to $26.761 million due to equity and debt financing, continued losses necessitate ongoing access to capital markets to fund operations.
• Dependence on R&D Revenue Growth [medium — operational]: Research and development revenue saw a substantial increase of 362.1% to $7.948 million in Q2 2025. The company's financial performance is increasingly reliant on the continued success and expansion of these R&D collaborations.
• Declining Short-term Investments [medium — financial]: Short-term investments decreased from $54.194 million at December 31, 2024, to $39.569 million as of June 30, 2025. This reduction, alongside increased long-term debt, suggests a strategic shift in asset allocation or utilization of funds.
• Decreasing Stockholders' Equity [medium — financial]: Total stockholders' equity declined from $66.927 million at December 31, 2024, to $55.631 million as of June 30, 2025. This decrease is primarily due to accumulated deficits, indicating that cumulative losses have outpaced capital contributions.
• Reduction in SG&A Expenses [low — operational]: Selling, general and administrative expenses decreased to $12.317 million in Q2 2025 from $15.671 million in Q2 2024. While this contributes to improved net loss, sustained cost management is crucial.

Industry Context

Codexis operates in the biotechnology and life sciences sector, focusing on enzyme engineering and development. The industry is characterized by high R&D investment, long development cycles, and significant regulatory oversight. Companies often rely on partnerships and collaborations for revenue generation and market access.

Regulatory Implications

As a biotechnology company, Codexis is subject to stringent regulations from bodies like the FDA. Compliance with manufacturing standards (e.g., GMP) and data integrity is critical. Any failure to meet these standards could lead to product recalls, fines, or delays in product approval, impacting financial performance.

What Investors Should Do

1. Monitor R&D revenue growth trajectory
2. Assess cash burn rate and future financing needs
3. Evaluate operating expense management
4. Analyze the impact of increased long-term debt

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the Q2 2025 financial results, showing significant revenue growth and reduced net loss.
• 2025-06-30: Balance Sheet Date — Reflects increased cash position of $26.761M and a decrease in total stockholders' equity to $55.631M.
• 2025-01-01: Beginning of Fiscal Year 2025 — Marks the start of the period for which year-to-date financial results are reported.
• 2024-12-31: End of Fiscal Year 2024 — Prior period balance sheet data for comparison, showing $19.264M in cash and $66.927M in stockholders' equity.

Glossary

Accumulated deficit

The cumulative net losses of a company that have not been offset by net income or additional paid-in capital. (Indicates the company has historically incurred more expenses than revenues, impacting stockholders' equity.)

Contract assets

Represents the company's right to consideration in exchange for goods or services that the company has transferred to a customer when that right is conditional on something other than the passage of time. (Shows revenue recognized but not yet billed, which decreased significantly from $4.375M to $1.279M.)

Unbilled receivables

Revenue that has been earned but not yet invoiced to the customer, often due to specific billing milestones or contractual terms. (Represents revenue earned but not yet recognized on the balance sheet, showing a slight increase.)

Right-of-use assets

An asset representing a lessee's right to use an underlying asset for the lease term under a lease contract. (Represents the value of leased assets, primarily for operating leases, which decreased slightly.)

Additional paid-in capital

The amount of capital that shareholders have paid to the corporation for stock in excess of the stock's par value. (Shows significant capital raised through stock issuance, increasing from $629.673M to $652.391M.)

Year-Over-Year Comparison

Compared to the prior year period, Codexis has demonstrated significant top-line improvement, with total revenues increasing by 92.1% in Q2 2025 to $15.328 million, largely driven by a 362.1% surge in R&D revenue. This revenue growth has contributed to a 41.7% reduction in net loss for the quarter, down to $13.272 million. However, for the six-month period, total revenues decreased slightly, while the net loss remained relatively stable. The company has also strengthened its cash position through equity and debt financing, but stockholders' equity has declined due to accumulated deficits.

Key Financial Figures

• $0.0001 — red Symbol(s) Common Stock, par value $0.0001 per share CDXS The Nasdaq Global Select

Filing Documents

• cdxs-20250630.htm (10-Q) — 1380KB
• ex-101codexis2ndamendmentt.htm (EX-10.1) — 7KB
• cdxs_20250630xex311.htm (EX-31.1) — 9KB
• cdxs_20250630xex312.htm (EX-31.2) — 9KB
• cdxs_20250630xex321.htm (EX-32.1) — 5KB
• 0001200375-25-000012.txt ( ) — 6650KB
• cdxs-20250630.xsd (EX-101.SCH) — 43KB
• cdxs-20250630_cal.xml (EX-101.CAL) — 79KB
• cdxs-20250630_def.xml (EX-101.DEF) — 169KB
• cdxs-20250630_lab.xml (EX-101.LAB) — 585KB
• cdxs-20250630_pre.xml (EX-101.PRE) — 383KB
• cdxs-20250630_htm.xml (XML) — 883KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements (Unaudited)

ITEM 1. Financial Statements (Unaudited) Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Comprehensive Loss 5 Condensed Consolidated Statements of Stockholders' Equity 6 Condensed Consolidated Statements of Cash Flows 8 Notes to Condensed Consolidated Financial Statements 10

Management's Discussion and Analysis of Financial Condition and Results of Operations

ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 22

Quantitative and Qualitative Disclosures about Market Risk

ITEM 3. Quantitative and Qualitative Disclosures about Market Risk 30

Controls and Procedures

ITEM 4. Controls and Procedures 31

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

ITEM 1. Legal Proceedings 32

Risk Factors

ITEM 1A. Risk Factors 32

Unregistered Sales of Equity Securities and Use of Proceeds

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 60

Defaults Upon Senior Securities

ITEM 3. Defaults Upon Senior Securities 60

Mine Safety Disclosures

ITEM 4. Mine Safety Disclosures 60

Other Information

ITEM 5. Other Information 60

Exhibits

ITEM 6. Exhibits 61

Signatures

Signatures 62 "Codexis," the Codexis logo, ECO Synthesis, and other trademarks or service marks of Codexis, Inc., appearing in this Quarterly Report on Form 10-Q are the property of Codexis, Inc. This Quarterly Report on Form 10-Q contains additional trade names, trademarks and service marks of others, which are the property of their respective owners. Solely for convenience, trademarks and trade names referred to in this Quarterly Report on Form 10-Q may appear without the or symbols. 2

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Codexis, Inc. Condensed Consolidated Balance Sheets (Unaudited) (In Thousands, Except Per Share Amounts) June 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 26,761 $ 19,264 Restricted cash, current 502 503 Short-term investments 39,569 54,194 Financial assets: Accounts receivable 12,271 11,920 Contract assets 1,279 4,375 Unbilled receivables 2,982 2,751 Total financial assets 16,532 19,046 Less: allowances ( 49 ) ( 162 ) Total financial assets, net 16,483 18,884 Inventories 1,945 1,799 Prepaid expenses and other current assets 3,469 4,128 Total current assets 88,729 98,772 Restricted cash 1,062 1,062 Investment in non-marketable equity securities 2,798 2,798 Right-of-use assets - Operating leases, net 27,260 28,700 Property and equipment, net 14,984 14,197 Goodwill 2,463 2,463 Other non-current assets 950 1,019 Total assets $ 138,246 $ 149,011 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 1,468 $ 2,838 Accrued compensation 7,262 11,410 Other accrued liabilities 3,406 6,223 Current portion of lease obligations - Operating leases 3,001 2,827 Deferred revenue 100 350 Total current liabilities 15,237 23,648 Deferred revenue, net of current portion 100 100 Long-term lease obligations - Operating leases 26,606 28,163 Long-term debt 39,373 28,905 Other long-term liabilities 1,299 1,268 Total liabilities 82,615 82,084 Commitments and Contingencies (Note 10) Stockholders' equity: Preferred stock, $ 0.0001 par value per share; 5,000 shares authorized, none issued and outstanding — — Common stock, $ 0.0001 par value per share; 200,000 shares authorized; 90,254 shares and 81,850 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 9 8 Additional paid-in capital 652,391 629,673 Accumulated other comprehensive income ( 3 ) 52 Accumulated deficit ( 596,766 ) ( 562,806 ) Total stockholders' equity 55,631 66,92

View Full Filing

View this 10-Q filing on SEC EDGAR